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To the Editor: Regarding the article by Goel et al.,1 we want
to mention a few points.
In the valuable paper by Goel et al.,1 a new technique
called minimally invasive limited ligation endoluminal-
assisted revision (MILLER) was introduced as the first-line
treatment for the management of steal syndrome. Their
technique not only eliminates difficulties of previous
approaches for the management of steal phenomenon,
but also reduces the rate of closing arteriovenous fistula
(AVF) due to decline in the blood flow of vascular access.
In a study by Morsey et al.,2 the incidence of steal syndrome
was even higher for arteriovenous grafts (AVGs; 4.3 vs
1.8% for AVFs), and this poses more difficulties for
vascular surgeons in countries where AVGs are used more
frequently.
We have shown that the creation of side-to-side elbow
AVFs diverts blood flow of the artery to the deep veins
through the perforating vein due to lower resistance of the
deep veins.3 To solve this problem, we introduced a simple
but efficient technique involving ligation of the perforating
vein. This method can be used as both a therapeutic and a
preventive strategy and was associated with salvage of 80% of
AVFs in a small series.4 With respect to the lower resistance of
the deep veins, it seems that a similar phenomenon occurs
after inserting AVGs as well. Thus, ligation of the perforating
vein may be effective for treatment and prevention of
steal syndrome in AVGs. Moreover, as shown in Figure 1, the
perforating vein can be approached by a small incision and
this procedure is ‘minimal invasive’. This is just a hypothesis
and has to be tested.
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Moini et al.1 have developed a procedure that increases
access resistance by simply eliminating flow decompression
into the deep veins. The authors assert that an access with
dialysis-associated steal syndrome can be corrected by
eliminating decompression into the deep venous system.
This is an accurate assertion given the resistance in the
access circuit will be higher and therefore shunt less blood.
However, the degree to which the resistance in the shunt
is altered cannot be incrementally controlled. This type
of imprecision caused the failures of traditional banding,
DRIL and RUDI procedures. If deep-vein ligation increases
the intra-access pressure too much, the access will
thrombose. Furthermore, even if the procedure provides
relief from steal symptoms, this may only be temporary
because the superficial veins may hypertrophy over time.
This hypertrophy may result in increased shunt as the
access matures. Steal symptoms may return and will
require further intervention (MILLER procedure) to
restore resistance balance.
If the superficial outflow system becomes thrombosed
or problematic, as it frequently does, prior ligation of the
perforating vein limits alternate outflow possibilities. This
is one of the reasons a graft has a shorter life span than a
fistula. A fistula has a surgical beginning and frequently
two, three, or four outflow veins. A graft has limited
outflow possibilities as compared with a fistula, making
it much more susceptible to stenosis and thrombosis. Any
A-V access venous drainage should include all possible
outflows to maximize longevity. Limiting an outflow
system by ligating the deep vein is likely to reduce the
durability and reliability of the access. Possibly, increasing
Figure 1 | The perforating vein is approached by an incision
about 1.5–2 cm below the antecubital crease. The perforating
vein is the vein without string.
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thrombosis rates to decrease a syndrome, which affects
only 1–8% of the accesses, seems to have an unfavorable
risk benefit profile.
The MILLER measured, standardized banding proce-
dure is successful because it allows for precise application
of resistance into a system.2 This procedure is minimally
invasive and can be performed multiple times just as easily
as it can be undone by simply dilating the band with an
angioplasty balloon. Ligation of the perforating vein
definitely seems to be a good idea in helping the superficial
veins to mature. However, it is unlikely to achieve a high
level of success in the treatment and prevention of DASS.
Although it is a feasible treatment, limited precision of
flow volume reduction and irreversibility lead to the same
problems that made traditional banding procedures
unsuccessful.
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To the Editor: Cotter et al.1 used United States Renal Data
System data from 14,001 incident patients to estimate the
dose–response relationship between epoetin (EPO) and
hematocrit. The authors used their analysis to infer the
maximum effective EPO dose and suggested that this should
inform Federal reimbursement policy. However, the analytic
approach used is inconsistent with FDA guidance and the
inferred maximum dose is not likely to be generalizable to the
US dialysis population. We think it is inadvisable to support
reimbursement policies based on inferential information
without careful consideration of the potential clinical
consequences.
When there is a time delay in clinical response (for
example, hemoglobin) following dosing, FDA recommends
parallel dose–response studies where patients receive constant
doses over fixed time periods with no target ceiling, such as
that proposed by Eschbach et al.2 However, Cotter et al.3 used
observational data containing frequent EPO dose titrations,
analyzed with marginal structural modeling. In studies of
flexible dosing, FDA recommends employing mixed-effects
regression, which accounts for interpatient variability in EPO
responsiveness. This is important because a broad range of
EPO doses (B40-fold) are required to achieve target
hemoglobin levels in individuals.4 The application of
unconventional analytics using observational data should
not supplant knowledge gained by the established approach
of controlled clinical trials designed to estimate dose–re-
sponse. Inferring a maximum effective dose from an
estimated mean might result in inadequate dosing for many
patients. Any new EPO policy should be based on the most
rigorous data and analyses, with careful assessment of the
potential impact.
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Critchlow et al.1 state that ‘the application of unconven-
tional analytics using observational data should not
supplant knowledge gained via the established approach
of controlled clinical trials designed to estimate dose–
response.’ We agree. However, controlled trials might
not provide a generalizable dose–response curve if more
sick patients who require higher doses of erythropoiesis
stimulating agents are under-represented because of
restricted enrollment criteria, patient’s underlying disease
burden, etc. Therefore, controlled trials based on such
restrictions are likely to underestimate the range of
erythropoiesis stimulating agent dose required in the
general hemodialysis population.
In contrast, our analysis of dose–response uses data
from an unselected medicare population and over the dose
range currently used by clinicians. We would encourage
Amgen and others to attempt to resolve the dose–response
issue with appropriately designed clinical trials in a
heterogeneous population. In the absence of such trials,
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